WallStSmart
ONC

BeiGene, Ltd.

NASDAQ: ONC · HEALTHCARE · BIOTECHNOLOGY

$295.27
+1.54% today

Updated 2026-04-30

Market cap
$33.18B
P/E ratio
120.52
P/S ratio
6.21x
EPS (TTM)
$2.48
Dividend yield
—
52W range
$218 – $385
Volume
0.2M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

BeiGene, Ltd. (ONC) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$295.27
Consensus
$374.75
+26.92%
2030 Target
$1,391.45
+371.25%
DCF
$1,738.29
+79.79% MoS
12 analysts:
7 Buy1 Hold0 Sell

Management guidance

BeiGene management guided 2026 operating revenue of RMB 43.6-45 billion (approximately $6.0-6.2 billion USD). Company has demonstrated 40.23% YoY growth in 2025 to $5.34B, with BRUKINSA driving the majority of revenue and expanding globally.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$2,298.92
$13.6B Rev × 20x P/S
Base case (2030)
$1,391.45
$13.6B Rev × 12x P/S
Bear case (2030)
$907.47
$13.6B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$2.5B$3.8B$5.3B$6.1B$7.4B$9.1B$11.1B$13.6B
Revenue growth—55.0%40.2%14.2%21.3%22.3%22.6%22.5%
EPS$-5.14$-5.08$4.15$3.80$5.20$6.80$8.50$10.50
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$635.23$756.23$907.47$1,119.21$1,391.45

Catalysts & risks

Growth catalysts
+ BRUKINSA continued global market penetration in CLL and mantle cell lymphoma
+ TEVIMBRA regulatory approvals and commercialization in gastroesophageal adenocarcinoma
+ Sonrotoclax BCL2 inhibitor expansion across multiple B-cell malignancies
+ Tislelizumab HCC approval (RATIONALE 301 Phase 3 positive - 8th positive Phase 3)
+ Strategic partnerships with Amgen, BMS, and Novartis expanding pipeline reach
+ Geographic expansion in India and emerging markets via distribution agreements
Key risks
- High P/E ratio (126.8x) leaves limited margin for clinical disappointment
- Competitive pressure from J&J, AbbVie, and other oncology leaders in core markets
- Reliance on BRUKINSA for ~65%+ of current revenue; pipeline concentration risk
- China market dynamics and potential pricing pressure on domestically-approved products
- Insider selling activity flagged; potential execution risks on Phase 3 programs
- Recent Jefferies downgrade to Hold suggests analyst confidence wavering on valuation

Methodology

BeiGene, Ltd.'s forward estimates are derived from AI-powered research synthesis combining analyst consensus from 12 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.